Richter’s syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Richter’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Richter’s syndrome: Overview
Richter’s Syndrome (RS), also known as Richter’s Transformation, is a rare complication of Chronic Lymphocytic Leukaemia (CLL) and/or Small Lymphocytic Lymphoma (SLL). It is characterised by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma. Richter’s Syndrome occurs in approximately 2-10% of all CLL/SLL patients during the course of their disease.
The most common symptoms of Richter’s Syndrome arise from a sudden and dramatic increase in the size of lymph nodes (also known as ‘lymphadenopathy’) characterised by usually painless areas of swelling in the neck, axilla, abdomen (most commonly in the spleen, also known as ‘splenomegaly’) or groin. Patients also often experience a dramatic increase in unexplained weight loss, fevers and night sweats (often collectively referred to as ‘B-symptoms’).
The definitive or differential diagnosis of Richter’s Syndrome is achieved by an excisional biopsy or CT/ultrasound guided core needle biopsy of an enlarged lymph node that is thought to be indicative of the Richter’s transformation. The current standard first-line treatment for this type of lymphoma is the immuno-chemotherapy using a combination of chemo drugs and a targeted anti-CD 20 monoclonal antibody. Other second-line chemotherapy regimens often used to treat this type of lymphoma (if non-responsive or ‘refractory’ to R-CHOP) include R-ICE, D-HAC, R-DHAP, GIVE, etc.
Report Highlights
This segment of the Richter’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Richter’s syndrome Emerging Drugs
Further product details are provided in the report..
Richter’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Richter’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Richter’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Richter’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Richter’s syndrome drugs.
Richter’s syndrome Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Richter’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Richter’s syndrome: Overview
Richter’s Syndrome (RS), also known as Richter’s Transformation, is a rare complication of Chronic Lymphocytic Leukaemia (CLL) and/or Small Lymphocytic Lymphoma (SLL). It is characterised by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma. Richter’s Syndrome occurs in approximately 2-10% of all CLL/SLL patients during the course of their disease.
The most common symptoms of Richter’s Syndrome arise from a sudden and dramatic increase in the size of lymph nodes (also known as ‘lymphadenopathy’) characterised by usually painless areas of swelling in the neck, axilla, abdomen (most commonly in the spleen, also known as ‘splenomegaly’) or groin. Patients also often experience a dramatic increase in unexplained weight loss, fevers and night sweats (often collectively referred to as ‘B-symptoms’).
The definitive or differential diagnosis of Richter’s Syndrome is achieved by an excisional biopsy or CT/ultrasound guided core needle biopsy of an enlarged lymph node that is thought to be indicative of the Richter’s transformation. The current standard first-line treatment for this type of lymphoma is the immuno-chemotherapy using a combination of chemo drugs and a targeted anti-CD 20 monoclonal antibody. Other second-line chemotherapy regimens often used to treat this type of lymphoma (if non-responsive or ‘refractory’ to R-CHOP) include R-ICE, D-HAC, R-DHAP, GIVE, etc.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Richter’s syndrome R&D. The therapies under development are focused on novel approaches for Richter’s syndrome.
This segment of the Richter’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Richter’s syndrome Emerging Drugs
- Duvelisib: Secura Bio
Further product details are provided in the report..
Richter’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Richter’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Richter’s syndrome
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Richter’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Richter’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Richter’s syndrome drugs.
Richter’s syndrome Report Insights
- Richter’s syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Richter’s syndrome drugs?
- How many Richter’s syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Richter’s syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Richter’s syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Richter’s syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- TG Therapeutics
- Secura Bio
- AstraZeneca
- Vincerx Pharma
- Merck & Co
- Umbralisib
- Duvelisib
- AZD4573
- VIP152
- MK-1026
Introduction
Executive Summary
Richter’s syndrome: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Richter’s syndrome– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Richter’s syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Richter’s syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Duvelisib: Secura Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
AZD4573: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Richter’s syndrome Key Companies
Richter’s syndrome Key Products
Richter’s syndrome- Unmet Needs
Richter’s syndrome- Market Drivers and Barriers
Richter’s syndrome- Future Perspectives and Conclusion
Richter’s syndrome Analyst Views
Richter’s syndrome Key Companies
Appendix
Executive Summary
Richter’s syndrome: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Richter’s syndrome– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Richter’s syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Richter’s syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Duvelisib: Secura Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
AZD4573: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Richter’s syndrome Key Companies
Richter’s syndrome Key Products
Richter’s syndrome- Unmet Needs
Richter’s syndrome- Market Drivers and Barriers
Richter’s syndrome- Future Perspectives and Conclusion
Richter’s syndrome Analyst Views
Richter’s syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Richter’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Richter’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Richter’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Richter’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
